// App-Quantinova.ai

3925 : Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)

Researchers

Presenter

  • Michael Hallek

Principal Investigators

  • Graeme Fraser

  • Brendan Purse

  • Jennie Zhang

  • Jay Mei

  • Asher Chanan-Khan

  • Anne-Sophie Michallet

  • Peter Hillmen

  • Jan Duerig

  • Stephanie A. Gregory

  • Matt Kalaycio

  • Stephan Stilgenbauer

  • Andreas Buehler

  • Thomas J. Kipps

Medical Centers

  • University of Ulm, Ulm, Germany

  • St James Institute of Oncology, Leeds, United Kingdom

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • Universtitatsklinikum Essen AoR, Essen, Germany

  • Centre Hospitalier Lyon-Sud, Pierre-Benite, France

  • Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

  • Juravinski Cancer Centre, Burlington, ON, Canada

Locations

  • Canada

  • Germany

  • United Kingdom

  • United States

  • France

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Chronic Lymphocytic Leukemia

  • Tumor lysis syndrome

  • Thrombocytopenia

  • Neutropenia

Biomarkers

  • RNA-binding protein FUS/TLS

Drug/Treatment

  • Bendamustine

  • Lenalidomide

  • Allopurinol

  • fludarabine tablet

  • ZAP70

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved